Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Copanlisib (Primary) ; Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 17 Nov 2022 Status changed from active, no longer recruiting to completed.
- 14 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 14 Apr 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2023.